As of May 22
| +0.17 / +9.19%|
The 2 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 9.25, with a high estimate of 10.50 and a low estimate of 8.00. The median estimate represents a +357.92% increase from the last price of 2.02.
The current consensus among 2 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.